MX2010002716A - Uso de slit, nefrina, efrina o semaforina para el tratamiento de enfermedades de cartilago. - Google Patents

Uso de slit, nefrina, efrina o semaforina para el tratamiento de enfermedades de cartilago.

Info

Publication number
MX2010002716A
MX2010002716A MX2010002716A MX2010002716A MX2010002716A MX 2010002716 A MX2010002716 A MX 2010002716A MX 2010002716 A MX2010002716 A MX 2010002716A MX 2010002716 A MX2010002716 A MX 2010002716A MX 2010002716 A MX2010002716 A MX 2010002716A
Authority
MX
Mexico
Prior art keywords
treatment
degenerative diseases
neuroendocrine factors
polypeptide
neuroendocrine
Prior art date
Application number
MX2010002716A
Other languages
English (en)
Spanish (es)
Inventor
Thomas Schubert
Anja Bosserhoff
Elisabeth Hustert
Original Assignee
Scil Technology Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP07018131A external-priority patent/EP2036921A1/en
Application filed by Scil Technology Gmbh filed Critical Scil Technology Gmbh
Publication of MX2010002716A publication Critical patent/MX2010002716A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
MX2010002716A 2007-09-14 2008-09-12 Uso de slit, nefrina, efrina o semaforina para el tratamiento de enfermedades de cartilago. MX2010002716A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07018131A EP2036921A1 (en) 2007-09-14 2007-09-14 Use of Slit, nephrin, ephrin or semaphorin for treatment of cartilage diseases
EP08006810 2008-04-03
PCT/EP2008/007579 WO2009033715A2 (en) 2007-09-14 2008-09-12 Neuroendocrine factors for treatment of degenerative diseases

Publications (1)

Publication Number Publication Date
MX2010002716A true MX2010002716A (es) 2010-07-05

Family

ID=40452588

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010002716A MX2010002716A (es) 2007-09-14 2008-09-12 Uso de slit, nefrina, efrina o semaforina para el tratamiento de enfermedades de cartilago.

Country Status (13)

Country Link
US (1) US20110002972A1 (cg-RX-API-DMAC7.html)
EP (1) EP2212344B1 (cg-RX-API-DMAC7.html)
JP (1) JP2010539123A (cg-RX-API-DMAC7.html)
KR (1) KR20100075493A (cg-RX-API-DMAC7.html)
CN (1) CN101821283A (cg-RX-API-DMAC7.html)
AU (1) AU2008297889A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0816784A8 (cg-RX-API-DMAC7.html)
CA (1) CA2699411A1 (cg-RX-API-DMAC7.html)
MX (1) MX2010002716A (cg-RX-API-DMAC7.html)
NZ (1) NZ583851A (cg-RX-API-DMAC7.html)
RU (1) RU2496790C2 (cg-RX-API-DMAC7.html)
WO (1) WO2009033715A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201001644B (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1400024B1 (it) * 2010-05-21 2013-05-17 Uni Politecnica Delle Marche Uso farmaceutico di semaforine.
UY33833A (es) * 2010-12-23 2012-07-31 Sanofi Sa Proteína de fusión Robo1-Fc para su uso en el tratamiento del hepatocarcinoma
ES3013463T3 (en) * 2011-07-04 2025-04-14 Mesoblast Inc Treating or preventing rheumatic disease
CN104582727B (zh) * 2012-06-15 2018-04-27 财团法人峩山社会福祉财团 利用Slit-Robo系统用于预防或治疗骨折或骨质疏松症的组合物
ES2442242B1 (es) * 2012-08-09 2014-11-25 Biotechnology Institute, I Mas D, S.L. Composición con factores de crecimiento destinada al tratamiento intranasal de una enfermedad neurodegenerativa u otra patología del sistema nervioso central, y su método de fabricación.
CN104119448A (zh) * 2013-04-26 2014-10-29 李华顺 含有富含亮氨酸重复序列的融合蛋白及其制法和应用
CN104119445A (zh) * 2013-04-26 2014-10-29 李华顺 含有富含亮氨酸重复序列的融合蛋白及其制法和应用
CN104119447A (zh) * 2013-04-26 2014-10-29 李华顺 含有富含亮氨酸重复序列的融合蛋白及其制法和应用
CN104119446A (zh) * 2013-04-26 2014-10-29 李华顺 含有富含亮氨酸重复序列的融合蛋白及其制法和应用
WO2015072527A1 (ja) * 2013-11-13 2015-05-21 国立大学法人大阪大学 ネトリン１含有破骨細胞形成抑制剤
HUE068789T2 (hu) 2014-03-14 2025-01-28 Univ New York State Res Found A csontnövekedés és a csontlebontás neurogén szabályozása
US11052175B2 (en) 2015-08-19 2021-07-06 Musculoskeletal Transplant Foundation Cartilage-derived implants and methods of making and using same
US20200397860A1 (en) * 2018-02-14 2020-12-24 Cornell University Slit and bone growth modulation
KR102353524B1 (ko) * 2019-02-27 2022-01-20 주식회사 대웅제약 알부민이 결합된, Slit3 단백질의 LRRD2를 포함하는 골 관련 질환 예방 또는 치료용 조성물
US20220340643A1 (en) * 2019-09-13 2022-10-27 Rutgers, The State University Of New Jersey Aav-compatible laminin-linker polymerization proteins
CN110841057B (zh) * 2019-11-19 2023-08-01 四川大学华西医院 一种神经导向因子Sema在制备治疗骨关节炎巴布膏剂中的应用
CN110721308B (zh) * 2019-11-19 2023-08-01 四川大学华西医院 一种用于治疗骨关节炎的药物复方制剂及其制备方法
CN110772632B (zh) * 2019-11-19 2023-08-11 四川大学华西医院 神经导向因子semaphorin 3a在制备治疗骨关节炎药物中的用途
CN110694051B (zh) * 2019-11-19 2023-08-01 四川大学华西医院 一种神经导向因子Sema在制备治疗骨关节炎注射剂中的应用
CN110711244B (zh) * 2019-11-19 2023-08-01 四川大学华西医院 一种神经导向因子Sema在制备治疗骨关节炎搽剂中的应用
CN110684805B (zh) * 2019-11-19 2023-08-01 四川大学华西医院 神经导向因子Sema基因重组慢病毒载体在制备治疗骨关节炎药物中的应用
US20240277861A1 (en) * 2021-07-26 2024-08-22 Purotech Bio, Inc. Anti-hepatitis b virus agent targeting host factor lipg

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2700117B1 (fr) * 1993-01-07 1995-02-03 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens.
JPH1116490A (ja) * 1997-06-26 1999-01-22 Kyocera Corp プラズマディスプレイパネル用隔壁の製造方法及びプラズマディスプレイパネル用基板
US20030032057A1 (en) * 1997-08-26 2003-02-13 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6342370B1 (en) * 1997-10-31 2002-01-29 Osiris Therapeutics, Inc. Human slit polypeptide and polynucleotides encoding same
JPH11164690A (ja) * 1997-12-05 1999-06-22 Asahi Chem Ind Co Ltd 脊椎動物スリット蛋白質
US6924355B2 (en) * 1998-09-01 2005-08-02 Genentech, Inc. PRO1343 polypeptides
EP1163336A2 (en) * 1999-03-17 2001-12-19 Washington University Vertebrate protein slit, dna sequence encoding it and uses thereof
WO2002006315A2 (en) * 2000-07-18 2002-01-24 Compugen Ltd. Novel nucleic acid and amino acid sequences
WO2002010217A2 (en) * 2000-08-02 2002-02-07 The Johns Hopkins University Endothelial cell expression patterns
WO2002012346A2 (en) * 2000-08-10 2002-02-14 Pharmacia Corporation A new slit-like protein obtained from a cdna library from hs-5 stromal cell line
WO2002081745A2 (en) * 2001-04-05 2002-10-17 Proskelia Pharmaceuticals Genes involved in osteogenesis, and methods of use
US20050014680A1 (en) * 2003-04-15 2005-01-20 Crabtree Gerald R. Methods and compositions for enhancing neuron growth and survival
US20060025335A1 (en) * 2004-01-30 2006-02-02 Kinane Thomas B Netrin compositions and methods of using the same
BRPI0720038A2 (pt) * 2006-12-11 2013-12-24 Univ Utah Res Found Métodos para inibir a permeabilidade vascular em tecido, para triar ou avaliar um agente que inibe a permeabilidade vascular, para tratar ou prevenir a síndrome da angústia respiratória, a retinopatia de prematuridade, a retinopatia diabética e a degeneração macular úmida em um indivíduo, para tratar indivíduos com sugestões repulsivas ou miméticos e para promover a angiogênese em um tecido, polipeptídeo isolado, ácido nucleico isolado, e, vetor

Also Published As

Publication number Publication date
BRPI0816784A8 (pt) 2016-01-19
EP2212344A2 (en) 2010-08-04
AU2008297889A1 (en) 2009-03-19
RU2496790C2 (ru) 2013-10-27
CA2699411A1 (en) 2009-03-19
NZ583851A (en) 2012-06-29
WO2009033715A2 (en) 2009-03-19
KR20100075493A (ko) 2010-07-02
ZA201001644B (en) 2011-03-30
JP2010539123A (ja) 2010-12-16
EP2212344B1 (en) 2014-03-26
RU2010114713A (ru) 2011-10-20
BRPI0816784A2 (pt) 2015-03-24
CN101821283A (zh) 2010-09-01
US20110002972A1 (en) 2011-01-06
WO2009033715A3 (en) 2010-03-18

Similar Documents

Publication Publication Date Title
MX2010002716A (es) Uso de slit, nefrina, efrina o semaforina para el tratamiento de enfermedades de cartilago.
WO2009086539A3 (en) Treatment and prophylaxis of amyloidosis
MX358013B (es) Materiales y metodos para el tratamiento o prevencion de enfermedades asociadas al her-3.
UA102867C2 (uk) Антитіла до cxcr4 та їх застосування у лікуванні раку
MY149630A (en) Antibodies against amyloid-beta peptide
EA201070636A1 (ru) Ингибирование рецептора белка, стимулирующего макрофаги (ron), и способы его лечения
MX2010008206A (es) Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf.
MX2008009886A (es) Anticuerpos que enlazan par-2.
IL194550A (en) Isolated antibodies or their fragments that bind to human protein tyrosine phosphate in a cell, their pharmaceutical preparations and their use
CR20110470A (es) Proteínas de union a il-17
MX2009012967A (es) Polipeptidos, dominios variables de anticuerpo y antagonistas.
TW200744642A (en) Novel peptides for use in the treatment of obesity
EA201000785A1 (ru) Композиции для доставки в легкие
MX2009012968A (es) Polipeptidos, dominios variables de anticuerpo y antagonistas.
AR113422A2 (es) Agentes tensioactivos reconstituidos que tienen propiedades mejoradas
CL2008000021A1 (es) Compuestos derivados de 2,4-dianilinopirimidinas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y cancer.
WO2009010968A3 (en) Disease treatment via antimicrobial peptides or their inhibitors
IL189452A0 (en) Therapy with cd4 binding peptides and radiation
MX2009006327A (es) Compuestos heterociclicos y metodos de uso de los mismos.
TN2009000194A1 (en) Novel antiproliferation antibodies
MX2009003039A (es) Utilizacion de un anticuerpo anti-cd151 para el tratamiento del cancer.
ATE443722T1 (de) Peptide und peptidderivate, ihre herstellung sowie ihre verwendung zur herstellung einer therapeutisch und/oder prophylaktisch wirksamen pharmazeutischen zusammensetzung
WO2008103378A3 (en) Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
MX337358B (es) Conjugados de disorazoles y sus derivados con moleculas de union con celulas, nuevos derivados de disorazol, procesos de fabricacion y usos de los mismos.
SE0401631D0 (sv) New Composition

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: FORMYCON GMBH

FA Abandonment or withdrawal